NGL Fine-Chem Limited (NGLFINE) - Total Assets
Based on the latest financial reports, NGL Fine-Chem Limited (NGLFINE) holds total assets worth Rs4.84 Billion INR (≈ $52.36 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See NGLFINE net asset value for net asset value and shareholders' equity analysis.
NGL Fine-Chem Limited - Total Assets Trend (2009–2025)
This chart illustrates how NGL Fine-Chem Limited's total assets have evolved over time, based on quarterly financial data.
NGL Fine-Chem Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
NGL Fine-Chem Limited's total assets of Rs4.84 Billion consist of 54.3% current assets and 45.7% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 1.4% |
| Accounts Receivable | Rs815.51 Million | 18.8% |
| Inventory | Rs512.70 Million | 11.8% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs3.97 Million | 0.1% |
| Goodwill | Rs1.53 Million | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how NGL Fine-Chem Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see NGLFINE market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: NGL Fine-Chem Limited's current assets represent 54.3% of total assets in 2025, a decrease from 66.0% in 2009.
- Cash Position: Cash and equivalents constituted 1.4% of total assets in 2025, down from 5.4% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 18.8% of total assets.
NGL Fine-Chem Limited Competitors by Total Assets
Key competitors of NGL Fine-Chem Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$208.73 Billion |
|
CSPC Pharmaceutical Group Limited
F:CVG
|
Germany | €46.00 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥1.60 Billion |
|
Shandong Keyuan Pharmaceutical Co. Ltd. A
SHE:301281
|
China | CN¥1.60 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.83 Billion |
|
Pfizer Inc
NYSE:PFE
|
USA | $208.73 Billion |
|
Merck & Company Inc
NYSE:MRK
|
USA | $129.55 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$1.83 Million |
NGL Fine-Chem Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 2.66 | 2.12 |
| Quick Ratio | 1.42 | 2.17 | 1.60 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs1.26 Billion | Rs1.47 Billion | Rs628.06 Million |
NGL Fine-Chem Limited - Advanced Valuation Insights
This section examines the relationship between NGL Fine-Chem Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.39 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 21.9% |
| Total Assets | Rs4.33 Billion |
| Market Capitalization | $147.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values NGL Fine-Chem Limited's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: NGL Fine-Chem Limited's assets grew by 21.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for NGL Fine-Chem Limited (2009–2025)
The table below shows the annual total assets of NGL Fine-Chem Limited from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs4.33 Billion ≈ $46.87 Million |
+21.90% |
| 2024-03-31 | Rs3.56 Billion ≈ $38.45 Million |
+23.85% |
| 2023-03-31 | Rs2.87 Billion ≈ $31.05 Million |
+3.67% |
| 2022-03-31 | Rs2.77 Billion ≈ $29.95 Million |
+33.29% |
| 2021-03-31 | Rs2.08 Billion ≈ $22.47 Million |
+35.25% |
| 2020-03-31 | Rs1.54 Billion ≈ $16.61 Million |
+8.04% |
| 2019-03-31 | Rs1.42 Billion ≈ $15.38 Million |
+9.98% |
| 2018-03-31 | Rs1.29 Billion ≈ $13.98 Million |
+27.69% |
| 2017-03-31 | Rs1.01 Billion ≈ $10.95 Million |
+30.63% |
| 2016-03-31 | Rs775.06 Million ≈ $8.38 Million |
+16.52% |
| 2015-03-31 | Rs665.17 Million ≈ $7.19 Million |
+19.11% |
| 2014-03-31 | Rs558.46 Million ≈ $6.04 Million |
+17.83% |
| 2013-03-31 | Rs473.96 Million ≈ $5.13 Million |
+27.44% |
| 2012-03-31 | Rs371.90 Million ≈ $4.02 Million |
+13.20% |
| 2011-03-31 | Rs328.53 Million ≈ $3.55 Million |
+29.53% |
| 2010-03-31 | Rs253.64 Million ≈ $2.74 Million |
+24.59% |
| 2009-03-31 | Rs203.57 Million ≈ $2.20 Million |
-- |
About NGL Fine-Chem Limited
NGL Fine-Chem Limited manufactures and sells pharmaceuticals and intermediates for usage in veterinary and human health in India, Europe, the Asia Pacific, the United States, and internationally. The company offers animal health pharmaceutical ingredients, such as homidium chloride, nitroxynil, clorsulon, parvaquone, buparvaquone, isometamidium chloride hydrochloride, toldimfos sodium, butaphosph… Read more